EDP1066 / Evelo Biosci - LARVOL DELTA

Impact of oral administration of single strain Lactococcus lactis spp. cremoris on immune responses to keyhole limpet hemocyanin immunization and gut microbiota: A randomized placebo-controlled trial in healthy volunteers. (PubMed, Front Immunol) - "cremoris (EDP1066) on the immune response to keyhole limpet hemocyanin (KLH)...The clinical impact of these effects awaits further investigations. trialsearch.who.int, trial ID NL7519."

Journal • Gastrointestinal Disorder • Immune Modulation • Immunology • Inflammation • Oncology • IL6 • TNFA

A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - P1a/1b; N=114; Completed; Sponsor: Evelo Biosciences, Inc.; N=168 ➔ 114; Active, not recruiting ➔ Completed

Clinical • Enrollment change • Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

Evelo Biosciences reports fourth quarter and full year 2019 financial results and business highlights (GlobeNewswire) - "EDP1066: Following completion of the final cohort of the EDP1066 Phase 1b trial, Evelo has decided to discontinue development of EDP1066....In the EDP1066 Phase 1b trial in mild to moderate atopic dermatitis and mild to moderate psoriasis, EDP1066 was well tolerated with no overall difference reported from placebo."

Discontinued • P1 data

A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - P1a/1b; N=168; Active, not recruiting; Sponsor: Evelo Biosciences, Inc.; Recruiting ➔ Active, not recruiting; N=96 ➔ 168; Trial completion date: Jun 2019 ➔ Mar 2020; Trial primary completion date: Jun 2019 ➔ Dec 2019

Clinical • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date

Evelo Biosciences announces further positive interim phase 1b clinical data in psoriasis and reports third quarter 2019 financial results (GlobeNewswire, Evelo Biosciences, Inc.) - EDP1815 plans to advance Phase 1b new formulation in psoriasis and atopic dermatitis….The Company expects to report initial clinical data from a cohort of individuals with mild to moderate atopic dermatitis to be dosed with a new formulation in the second quarter of 2020. EDP1066 – Phase 1b new formulation in atopic dermatitis. Evelo expects to report initial clinical data from a cohort of individuals with mild to moderate atopic dermatitis, dosed with a new formulation, in the first quarter of 2020.”

Clinical data • P1 data

Evelo Biosciences announces positive interim phase 1b clinical data and provides second quarter 2019 financial results (GlobeNewswire) - "Evelo is focusing the current EDP1066 Phase 1b trial on investigating the activity of a new formulation, which was up to 30-fold more potent in preclinical models, in a cohort of mild to moderate atopic dermatitis patients. Evelo expects to report data from this cohort in the first quarter of 2020."

P1 data

Evelo Biosciences Announces Positive Interim Phase 1b Clinical Data and Provides Second Quarter 2019 Financial Results (GlobeNewswire, Evelo Biosciences, Inc.) - "EDP1815 and EDP1066 were Well Tolerated with No Overall Difference Reported from Placebo-. -Positive EDP1066 Blood Immune Cell Biomarker Data in Psoriasis Patients at High Dose...Today, Evelo reports positive EDP1066 biomarker data at the high dose from its ongoing Phase 1b trial in patients with mild to moderate psoriasis."

Biomarker • Clinical data

Evelo Biosciences reports first quarter 2019 financial results and recent business highlights (GlobeNewswire) - "EDP1066 - Phase 1b...Healthy volunteers and psoriasis patients - Evelo expects to complete dosing this quarter and to report initial clinical data early in the third quarter of 2019....New formulation - Evelo expects to report initial clinical data from cohorts of psoriasis...during the fourth quarter of 2019..."

Clinical data • P1 data • Trial status

Newly added product (GlobeNewswire) - P1, Psoriasis, Atopic Dermatitis

Pipeline update